Mereo BioPharma Group
Update in progressMREO (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Mereo BioPharma Group plc is a London-based biopharmaceutical company developing therapies for rare diseases in the UK and US. Its pipeline includes Setrusumab for osteogenesis imperfecta; Alvelestat for AAT-deficiency–related lung disease; Vantictumab for autosomal dominant osteopetrosis type 2; Leflutrozole for hypogonadotropic hypogonadism; Navicixizumab, Etigilimab and Acumapimod in cancer and COPD trials. It licenses Navicixizumab to Feng Biosciences and Leflutrozole to ReproNovo, with AstraZeneca collaboration. Founded 2015.
Company score
- Sentiment
- -0.06
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.00
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited Kingdom
- CEODr. Denise Vera Scots-Knight Ph.D.
- Founded2015
- Employees39
- Websitewww.mereobiopharma.com
Identifiers
- ISINUS5894921072
- FIGIBBG00KFWZC67
- LEI213800U8JQHIJOS5AS09
- CUSIP589492107